CN1135715A - 新的组合物 - Google Patents
新的组合物 Download PDFInfo
- Publication number
- CN1135715A CN1135715A CN94194238A CN94194238A CN1135715A CN 1135715 A CN1135715 A CN 1135715A CN 94194238 A CN94194238 A CN 94194238A CN 94194238 A CN94194238 A CN 94194238A CN 1135715 A CN1135715 A CN 1135715A
- Authority
- CN
- China
- Prior art keywords
- weight
- described compositions
- compositions
- composition
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
含有乳膏基质的药用或兽用组合物，所述乳膏基质包括矿物油；一种或多种脂肪醇或脂肪酯；聚氧乙烯醚或酯表面活性剂；以及水。
Description
本发明涉及用作为治疗用化合物载体的新组合物。尤其是本发明涉及用作为局部应用有效治疗药物(如抗菌素)的通常所说“乳膏”的赋形剂。
EP-A-0 069 423(Gist-Brocades)公开了用作为局部药用组合物的通常所说的”脂肪-乳膏”，它含有50-80％(按重量计)脂肪物质、1.5-5％(按重量计)亲水的非离子型表面活性剂以及治疗药物。优选的组合物基质包括十六烷基硬脂醇、液体石蜡、白色软石蜡和西土马哥1000。
EP-A-0 251 434(Beecham Group)尤其公开了含有抗菌素莫匹罗星的各种乳膏配方。一个具体的实施例含有1-3％(按重量计)莫匹罗星(或其盐)、25-60％(按重量计)液体石蜡、20-50％(按重量计)水以及3-30％(按重量计)乳化剂。其实施例6公开了含有液体石蜡(42％)、硬脂醇(16.4％)和西土马哥1000(3.6％)的乳膏。
含有莫匹罗星的局部用抗菌组合物在英国由Beecham ResearchLaboratories的商品名Bactroban Ointment和Bactroban Nasal进行销售。第一个产品为含有水可溶性聚乙二醇基质的软膏剂，而第二个产品为含有甘油酯的莫匹罗星钙盐的白色软石蜡为基质的软膏剂。
由上述先有技术公开的广泛的组合物中，现在我们发现了与先有技术配方相比具有改进的制剂特性的严格配方。
本发明提供了含有乳膏基质和治疗药物的药用或兽用的组合物，其特征在于该乳膏基质包括
45-60％，优选50-55％按重量计的矿物油；
5-15％，优选5-10％按重量计的一种或多种脂肪醇或脂肪酯；
4-8％，优选5-7％按重量计的聚氧乙烯醚或酯表面活性剂；以及
20-35％，优选25-35％按重量计的水。
上述组合物中的百分比的组合物总重量为基准，该组合物一般还含有1-3％按重量计的治疗药物(如抗菌素)。
矿物油和脂肪醇或酯一起占组合物重量的50-75％是合适的，优选占55-70％，更优选占55-65％。矿物油与脂肪醇或酯的比例为1∶3-1∶12是合适的，优选1∶5-1∶11(按重量计)。
所述治疗药物可以是任一在局部应用有效的药物。作为适合局部应用的抗菌素，尤其可以提到的有莫匹罗星，特别是它的钙盐，尤其是它的二水合物。莫匹罗星或其盐占配方重量的1-3％是合适的，通常为约2％(以游离酸的重量表示)。
这里应用的术语“矿物油”包括适用于局部药用组合物或兽药组合物中的任何一种矿物油，并且包括矿物油(USP)、轻矿物油(NF)、液体石蜡(BP)和轻液体石蜡(BP)。称作为矿物油(USP)的矿物油是尤其适用的。
作为脂肪醇或蜡，可以应用于药用组合物或兽药组合物中的任一脂肪醇或酯，例如硬脂醇、十六烷醇、十六烷基硬脂醇、十四烷基醇和甘油单硬脂酸酯。应用硬脂醇与十六烷基醇的混合物是合适的。
在本发明中应用的聚氧乙烯酯或醇是一种起非离子表面活性剂作用的物质。如上面所引的EP-A-0 069 423中所示，作为表面活性剂它有利于HLB值为14或14以上。合适的物质包括聚乙二醇单鲸蜡基醚，例如以商品名西土马哥1000销售的物质，以及例如以商品名聚山梨醇酯-60销售的聚氧乙烯山梨糖醇单硬脂酸酯和以商品名吐温80销售的聚氧乙烯山梨糖醇单油酸酯。
本发明组合物还可以包括少量的常用添加剂如粘滞度改进剂例如苍耳胶，以及防腐剂例如苯氧基乙醇或苄醇(包括它们的混合物)。对于某些治疗药物，为了保持合适的pH值，需要加入缓冲剂。
本发明中优选的组合物包括50-55％(按重量计)矿物油，合适的有矿物油(USP)；5-10％(按重量计)脂肪醇或酯，合适的有十六烷基醇或硬脂醇或它们的混合物；5-7％的聚氧乙烯醚或酯表面活性剂，合适的有聚乙二醇单鲸蜡基醚例如西土马哥1000；25-35％(按重量计)水以及1-3％(约2％是合适的)(按重量计)莫匹罗星钙盐，尤其是其二水合物盐(以游离酸的重量表示)。
该乳膏基质可以按本技术领域熟知的一般方法进行制备。一般来讲，合适的方法包括以合适的相当量按任一方便的顺序将各个乳膏成分混合，然后如果需要，调节pH至最终需要的数值。例如，在一升高的温度(例如60-70℃)，将该基质的各个成分一起混合，直至形成乳状液。在该已乳化的乳膏基质冷却之后加入治疗药物，或者如果应用的温度合适，可以在基质的各个成分混合时加入治疗药物。
本发明组合物供药用或兽药用。在上述步骤中按常用的无菌步骤可以按无菌条件任意地得到组合物。另外，在无菌条件下使无菌的各成分进行混合。
另一方面，本发明提供了用于治疗的药用或兽用的组合物。
此外，本发明另一方面，该乳膏基质本身可以用作为湿润的乳膏或润肤剂而无需有治疗药物。
下面的实施例详细叙述了本发明的组合物。实施例1
％(按重量计)矿物油(USP) 54.9聚乙二醇(1000)单鲸蜡基醚* 5.0硬脂醇(NF) 3.5十六烷基醇(NF) 3.5苯氧基乙醇 0.5莫匹罗星钙盐 2.4苍耳胶 0.2纯化水 30.0*西土马哥1000实施例2
％(按重量计)矿物油(USP) 51.9聚乙二醇(1000)单鲸蜡基醚 6.0硬脂醇(NF) 3.5十六烷基醇(NF) 3.5苯氧基乙醇 0.5苄基醇 1.0莫匹罗星钙盐 2.4苍耳胶 0.2纯化水 31.0实施例3
％(按重量计)矿物油(USP) 50.9聚乙二醇(1000)单鲸蜡基醚 6.0硬脂醇(NF) 3.5十六烷基醇(NF) 3.5苯氧基乙醇 0.5苄基醇 1.0莫匹罗星钙盐 2.4苍耳胶 0.2纯化水 32.0
Claims (16)
1.含有乳膏基质和治疗药物的药用或兽用组合物，其特征在于所述乳膏基质包括：45-60％(按重量计)矿物油；5-15％(按重量计)一种或多种脂肪醇或酯；4-8％(按重量计)聚氧乙烯醚或酯表面活性剂；以及20-35％(按重量计)水。
2.权利要求1所述的组合物，该组合物含有50-55％(按重量计)矿物油。
3.权利要求1或2所述的组合物，该组合物含有5-10％(按重量计)一种或多种脂肪醇或酯。
4.权利要求1-3中任何一项所述的组合物，其中脂肪醇为硬脂醇与十六烷基醇的混合物。
5.权利要求1-4中任何一项所述的组合物，该组合物含有5-7％(按重量计)聚氧乙烯醚或酯表面活性剂。
6.权利要求1-5中任何一项所述的组合物，其中表面活性剂为聚乙二醇单鲸蜡基醚。
7.权利要求1-6中任何一项所述的组合物，该组合物含有25-35％(按重量计)水。
8.权利要求1-7中任何一项所述的组合物，该组合物含有1-3％(按重量计)治疗药物。
9.权利要求8所述的组合物，其中治疗药物为抗菌素。
10.权利要求9所述的组合物，其中抗菌素为莫匹罗星或其盐。
11.权利要求10所述的组合物，其中所述盐为莫匹罗星钙盐二水合物。
12.权利要求1-11中任何一项所述的组合物还含有选自苯氧基乙醇或苄基醇或为它们混合物的防腐剂。
13.药用或兽用的组合物，该组合物含有50-55％(按重量计)矿物油；5-10％(按重量计)脂肪醇或酯；5-7％的聚氧乙烯醚或酯表面活性剂；30-35％(按重量计)水以及1-3％(按重量计)莫匹罗星钙盐(以其游离酸的重量表示)。
14.上述任一项权利要求所述的用于治疗的组合物。
15.制备权利要求1-13中任何一项所述组合物的方法，该方法包括将各个成分以合适的相当量按任一方便的顺序进行混合，然后如果需要，调节PH至最终需要的数值。
16.实质上参考上面任一实施例方法制备的权利要求1所述的组合物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9321876.6 | 1993-10-22 | ||
| GB939321876A GB9321876D0 (en) | 1993-10-22 | 1993-10-22 | Novel composition |
| GB9322288.3 | 1993-10-29 | ||
| GB939322288A GB9322288D0 (en) | 1993-10-29 | 1993-10-29 | Novel composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1135715A true CN1135715A (zh) | 1996-11-13 |
| CN1102410C CN1102410C (zh) | 2003-03-05 |
Family
ID=26303736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94194238A Expired - Lifetime CN1102410C (zh) | 1993-10-22 | 1994-10-20 | 莫匹罗星钙盐的乳膏组合物 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6025389A (zh) |
| EP (1) | EP0727979B1 (zh) |
| JP (1) | JPH09506865A (zh) |
| KR (1) | KR100374462B1 (zh) |
| CN (1) | CN1102410C (zh) |
| AP (1) | AP608A (zh) |
| AT (1) | ATE202467T1 (zh) |
| AU (1) | AU692486B2 (zh) |
| BG (1) | BG62912B1 (zh) |
| BR (1) | BR9407840A (zh) |
| CA (1) | CA2174658C (zh) |
| CZ (1) | CZ292223B6 (zh) |
| DE (1) | DE69427589T2 (zh) |
| DK (1) | DK0727979T3 (zh) |
| ES (1) | ES2157996T3 (zh) |
| FI (1) | FI116931B (zh) |
| GR (1) | GR3036591T3 (zh) |
| HK (1) | HK1012284A1 (zh) |
| HU (1) | HU221853B1 (zh) |
| NO (1) | NO313446B1 (zh) |
| NZ (1) | NZ275282A (zh) |
| OA (1) | OA10361A (zh) |
| PL (1) | PL177592B1 (zh) |
| PT (1) | PT727979E (zh) |
| RO (1) | RO112987B1 (zh) |
| SK (1) | SK280222B6 (zh) |
| UA (1) | UA39896C2 (zh) |
| WO (1) | WO1995010999A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335122A (zh) * | 2011-06-21 | 2012-02-01 | 北京协和药厂 | 一种莫匹罗星软膏及其制备方法 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998014189A1 (en) * | 1996-10-01 | 1998-04-09 | Smithkline Beecham Corporation | Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms |
| CO4910145A1 (es) * | 1996-10-01 | 2000-04-24 | Smithkline Beecham Corp | Uso |
| WO1999012520A1 (en) * | 1997-09-11 | 1999-03-18 | Smithkline Beecham Plc | Compositions adapted for prolonged residence in the nasal pharynx |
| IL123143A (en) * | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| GB9808470D0 (en) | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
| IL137363A (en) * | 2000-07-18 | 2005-12-18 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| EP1619947A4 (en) * | 2003-05-01 | 2006-05-31 | Replidyne Inc | ANTIBACTERIAL COMPOSITIONS AND ASSOCIATED METHODS |
| US20050123576A1 (en) * | 2003-12-03 | 2005-06-09 | Ilana Lavon | Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| WO2008007182A2 (en) * | 2006-07-07 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions of mupirocin or pharmaceutically acceptable salts or esters thereof |
| JP5932762B2 (ja) | 2010-03-30 | 2016-06-15 | ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 微生物感染に対する治療薬 |
| JP2013532716A (ja) | 2010-08-05 | 2013-08-19 | ヘルパービー セラピューティクス リミテッド | ピロロキノリン化合物と、β−ラクタム系抗微生物剤、ムピロシンまたはクロルヘキシジンとの組み合わせ |
| GB201013207D0 (en) | 2010-08-05 | 2010-09-22 | Helperby Therapeutics Ltd | Novel combination |
| GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| US20130245060A1 (en) | 2010-10-08 | 2013-09-19 | Helperby Therapeutics Limited | Novel composition |
| EP2704704B1 (en) | 2011-05-03 | 2018-09-26 | DuPont Nutrition Biosciences ApS | Probiotic bacteria for the topical treatment of skin disorders |
| GB201107755D0 (en) | 2011-05-10 | 2011-06-22 | Helperby Therapeutics Ltd | Novel compounds |
| DE102012215511A1 (de) | 2012-08-31 | 2014-06-12 | Schülke & Mayr GmbH | Verfahren zur Herstellung einer Bispyridiniumalkan enthaltenden halbfesten Zubereitung |
| GB201305277D0 (en) | 2013-03-22 | 2013-05-01 | Helperby Therapeutics Ltd | Novel combination and use |
| GB201307989D0 (en) | 2013-05-02 | 2013-06-12 | Helperby Therapeutics Ltd | Novel combinations and use |
| AU2014377875B2 (en) | 2013-12-17 | 2018-07-19 | Dr. Reddy's Laboratories Sa | Pediculicidal composition |
| GB201401617D0 (en) | 2014-01-30 | 2014-03-19 | Helperby Therapeutics Ltd | Novel combination and use |
| US10335454B2 (en) | 2014-12-18 | 2019-07-02 | Helperby Therapeutics Limited | Combination and use |
| WO2016133471A1 (en) | 2015-02-20 | 2016-08-25 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. | A topical composition comprising mupirocin and dexpanthenol |
| GB201518969D0 (en) | 2015-10-27 | 2015-12-09 | Helperby Therapeutics Ltd | Triple combination |
| KR102340006B1 (ko) | 2016-04-19 | 2021-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 아토피 피부염을 치료하기 위한 그램 음성 종의 용도 |
| US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| GB201610869D0 (en) | 2016-06-22 | 2016-08-03 | Helperby Therapeutics Ltd | Combination |
| GB201620095D0 (en) | 2016-11-28 | 2017-01-11 | Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And | Novel use |
| GB201709193D0 (en) | 2017-06-09 | 2017-07-26 | Helperby Therapeutics Ltd | Combination |
| WO2019141957A1 (en) | 2018-01-19 | 2019-07-25 | Cado Biotechnology Ivs | N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof |
| WO2019217203A1 (en) | 2018-05-11 | 2019-11-14 | Forte Biosciences, Inc | Compositions for the treatment of skin conditions |
| US10709663B2 (en) | 2018-10-17 | 2020-07-14 | Glenmark Pharmaceuticals, Inc., Usa | Mupirocin cream in pump device |
| IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
| WO2021203136A1 (en) * | 2020-03-31 | 2021-10-07 | Chemistryrx | Methods for treating hyperpigmentation and compositions for same |
| AU2022251858A1 (en) | 2021-03-30 | 2023-09-07 | International N&H Denmark Aps | Compositions and methods for treating and preventing gastrointestinal inflammation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758686A (en) * | 1971-12-07 | 1973-09-11 | American Cyanamid Co | Method of using steroid acetonides |
| US3934013A (en) * | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| NZ200918A (en) * | 1981-07-02 | 1985-07-31 | Gist Brocades Nv | Stable fatty oil-in-water emulsion cream for topical application |
| GB8530796D0 (en) * | 1985-12-13 | 1986-01-22 | Beecham Group Plc | Pharmaceutical composition |
| IE59628B1 (en) * | 1986-06-26 | 1994-03-09 | Beecham Group Plc | Treatment of fungal infections |
| US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
-
1994
- 1994-10-20 CN CN94194238A patent/CN1102410C/zh not_active Expired - Lifetime
- 1994-10-20 AU AU80847/94A patent/AU692486B2/en not_active Expired
- 1994-10-20 NZ NZ275282A patent/NZ275282A/en not_active IP Right Cessation
- 1994-10-20 HU HU9601030A patent/HU221853B1/hu active IP Right Grant
- 1994-10-20 DK DK94931943T patent/DK0727979T3/da active
- 1994-10-20 WO PCT/US1994/012026 patent/WO1995010999A1/en active IP Right Grant
- 1994-10-20 AP APAP/P/1996/000798A patent/AP608A/en active
- 1994-10-20 AT AT94931943T patent/ATE202467T1/de active
- 1994-10-20 CZ CZ19961120A patent/CZ292223B6/cs not_active IP Right Cessation
- 1994-10-20 ES ES94931943T patent/ES2157996T3/es not_active Expired - Lifetime
- 1994-10-20 BR BR9407840A patent/BR9407840A/pt not_active Application Discontinuation
- 1994-10-20 DE DE69427589T patent/DE69427589T2/de not_active Expired - Lifetime
- 1994-10-20 PL PL94314038A patent/PL177592B1/pl unknown
- 1994-10-20 UA UA96041570A patent/UA39896C2/uk unknown
- 1994-10-20 EP EP94931943A patent/EP0727979B1/en not_active Expired - Lifetime
- 1994-10-20 JP JP7512208A patent/JPH09506865A/ja active Pending
- 1994-10-20 RO RO96-00817A patent/RO112987B1/ro unknown
- 1994-10-20 KR KR1019960702041A patent/KR100374462B1/ko not_active IP Right Cessation
- 1994-10-20 CA CA002174658A patent/CA2174658C/en not_active Expired - Lifetime
- 1994-10-20 PT PT94931943T patent/PT727979E/pt unknown
- 1994-10-20 SK SK495-96A patent/SK280222B6/sk not_active IP Right Cessation
-
1996
- 1996-04-12 BG BG100501A patent/BG62912B1/bg unknown
- 1996-04-19 FI FI961720A patent/FI116931B/fi not_active IP Right Cessation
- 1996-04-19 NO NO19961588A patent/NO313446B1/no not_active IP Right Cessation
- 1996-04-22 OA OA60817A patent/OA10361A/en unknown
-
1997
- 1997-07-25 US US08/903,255 patent/US6025389A/en not_active Expired - Lifetime
-
1998
- 1998-12-16 HK HK98113614A patent/HK1012284A1/xx not_active IP Right Cessation
-
2001
- 2001-09-11 GR GR20010401448T patent/GR3036591T3/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335122A (zh) * | 2011-06-21 | 2012-02-01 | 北京协和药厂 | 一种莫匹罗星软膏及其制备方法 |
| CN102335122B (zh) * | 2011-06-21 | 2013-04-17 | 北京协和药厂 | 一种莫匹罗星软膏及其制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1135715A (zh) | 新的组合物 | |
| CA2225286C (en) | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof | |
| DE60131881T2 (de) | Topische zusammensetzung enthaltend mindestens ein vitamin d oder vitamin d analogon und mindestens ein corticosteroid | |
| CN1239427A (zh) | Mupirocin在制备用于治疗与病原生物体鼻咽建群有关的细菌感染的药物中的应用 | |
| EP0231621B1 (en) | Topical pharmaceutical composition comprising pseudomonic acid or a salt or ester thereof and a corticosteroid | |
| IE49527B1 (en) | Preparing compositions comprising isosorbide dinitrate | |
| IE910068A1 (en) | Topical compositions | |
| KR20020038595A (ko) | 피부 침투제를 포함하는 국소용 제제 및 그의 용도 | |
| EP0445540B1 (en) | Antimycotic external imidazole preparations | |
| JPH07304669A (ja) | 痔疾治療用組成物 | |
| US6979454B1 (en) | Biologically active composition | |
| GB2327344A (en) | Pharmaceutical compositions containing phenytoin and either an azole anti-fungal/anti-bacterial agent and/or a silver salt for topical application | |
| RU2148998C1 (ru) | Фармацевтическая или ветеринарная композиция (варианты) и способ получения композиции | |
| JPH10101555A (ja) | ゲルクリーム剤 | |
| TW202228713A (zh) | 外用乳化組成物 | |
| CA1231052A (en) | Vehicle suitable for use in medicinal preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20141020 Granted publication date: 20030305 |